|

Diabetes Clinical Trials in Arizona

50 recruiting studies across 3 cities

Browse by City

Mesa
39 trials
Phoenix
39 trials
Tucson
25 trials

All Trials in Arizona

Phase
Trial Phase Dist.
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseasePhase 3<1 mi
Cardiovascular Kidney and Metabolic Health Assessment and Patient EmpowermentN/A<1 mi
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)Phase 3<1 mi
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesPhase 2<1 mi
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinPhase 3<1 mi
A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting—<1 mi
A Clinical Investigation Evaluating Wound Closure with OptiPulse™ Versus SOC in the Treatment of Non-Healing DFU'sN/A<1 mi
Efficacy of Placental Membrane Dressings in Accelerating Diabetic Foot HealingPhase 4<1 mi
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic RetinopathyPhase 2<1 mi
A Study of Lower Radiotherapy Dose to Treat Children With CNS GerminomaPhase 2<1 mi
EDX110 Randomized Control Trial for Treatment of DFUsN/A<1 mi
Maturation of Arteriovenous Fistula With Automated Sonography Assessments TrialN/A<1 mi
Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes MellitusN/A<1 mi
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightPhase 3<1 mi
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have DiabetesPhase 3<1 mi
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)—<1 mi
DISCOVERY of Risk Factors for Type 2 Diabetes in Youth—<1 mi
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatidePhase 2<1 mi
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomesPhase 4<1 mi
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing DialysisPhase 2/3<1 mi
American Indian Chronic Renal Insufficiency Cohort Study (AI-CRIC Study)—<1 mi
Smart Walk: A Culturally Tailored Smartphone-Delivered Physical Activity Intervention for African American WomenPhase 2<1 mi
Early Tracking of Childhood Health Determinants (ETCHED) Study—<1 mi
Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance ProblemsN/A<1 mi
Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot UlcersN/A<1 mi
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)Phase 23 mi
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)Phase 33 mi
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular EventsN/A3 mi
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesPhase 33 mi
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityPhase 33 mi
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesPhase 33 mi
DFC 004 Biomarkers for Active Diabetic Foot Ulcers—3 mi
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)Phase 1/23 mi
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 DiabetesPhase 23 mi
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) TrialPhase 23 mi
Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot UlcersN/A3 mi
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesPhase 33 mi
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney DiseasePhase 33 mi
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)Phase 33 mi
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal InsulinPhase 23 mi
Diabetic Foot Ulcer (DFU) Biofilm Infection and Recurrence—3 mi
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintidePhase 33 mi
WatchWell: Simple and Practical Strategies to Reduce the Negative Health Impact of Sedentary Screen TimeN/A5 mi
Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project—8 mi
Gastroparesis Registry 4—8 mi
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesPhase 38 mi
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 DiabetesPhase 38 mi
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 DiabetesPhase 38 mi
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)Phase 1/28 mi
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have DiabetesPhase 315 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.